An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia

References

• Derosa G, Maffioli P. The cardiometabolic risk: a new concept for old diseases. Nutrafoods. 2019;1:40–43.
   Google Scholar
• Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344–1351. doi:10.1038/nm1135
   PubMed Web of Science ®Google Scholar
• Affuso F, Mercurio V, Ruvolo A, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol. 2012;4(3):77–83. doi:10.4330/wjc.v4.i3.77
   PubMedGoogle Scholar
• Derosa G, Bonaventura A, Bianchi L, et al. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J Biol Regul Homeost Agents. 2013;27(3):717–728.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59(2):285–292. doi:10.1016/j.metabol.2009.07.029
   PubMed Web of Science ®Google Scholar
• Stohs SJ, Miller H, Kaats GR. A review of the efficacy and safety of banaba (Lagerstroemia speciosa L.) and corosolic acid. Phytother Res. 2012;26(3):317–324. doi:10.1002/ptr.3664
   PubMed Web of Science ®Google Scholar
• Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr. 1998;17(6):548–555. doi:10.1080/07315724.1998.10718802
   PubMed Web of Science ®Google Scholar
• Broadhurst CL, Domenico P. Clinical studies on chromium picolinate supplementation in diabetes mellitus–a review. Diabetes Technol Ther. 2006;8(6):677–687. doi:10.1089/dia.2006.8.677
   PubMedGoogle Scholar
• Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55:2256–2264. doi:10.2337/db06-0006
   PubMed Web of Science ®Google Scholar
• Hayashi T, Maruyama H, Kasai R, et al. Ellagitannins from Lagerstroemia speciosa as activators of glucose transport in fat cells. Planta Med. 2002;68:173–175. doi:10.1055/s-2002-20251
   PubMed Web of Science ®Google Scholar
• Murakami C, Myoga K, Kasai R, et al. Screening of plant constituents for effect on glucose transport activity in Ehrlich ascites tumour cells. Chem Pharm Bull. 1993;41:2129–2131. doi:10.1248/cpb.41.2129
   PubMed Web of Science ®Google Scholar
• Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr. 1998;17:555–584. doi:10.1080/07315724.1998.10718802
   Google Scholar
• Jiménez-Osorio AS, Monroy A, Alavez S. Curcumin and insulin resistance-molecular targets and clinical evidences. Biofactors. 2016;42(6):561–580. doi:10.1002/biof.v42.6
   PubMed Web of Science ®Google Scholar
• Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014;28(12):1770–1777. doi:10.1002/ptr.5197
   PubMed Web of Science ®Google Scholar
• Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med. 2014;22(5):851–857. doi:10.1016/j.ctim.2014.07.006
   PubMed Web of Science ®Google Scholar
• Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012;35(11):2121–2127. doi:10.2337/dc12-0116
   PubMed Web of Science ®Google Scholar
• Kato M, Nishikawa S, Ikehata A, et al. Curcumin improves glucose tolerance via stimulation of glucagon-like peptide-1 secretion. Mol Nutr Food Res. 2017;61:3. doi:10.1002/mnfr.201600471
   Google Scholar
• Muscogiuri G, Palomba S, Laganà AS, Orio F. Inositols in the treatment of insulin-mediated diseases. Int J Endocrinol. 2016;2016:3058393.
   PubMed Web of Science ®Google Scholar
• Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013;29(4):375–379. doi:10.3109/09513590.2012.743020
   PubMed Web of Science ®Google Scholar
• Laganà AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet. 2015;291(5):1181–1186. doi:10.1007/s00404-014-3552-6
   PubMed Web of Science ®Google Scholar
• Corrado F, D’Anna R, Di Vieste G, et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011;28(8):972–975. doi:10.1111/j.1464-5491.2011.03284.x
   PubMed Web of Science ®Google Scholar
• D’Anna R, Scilipoti A, Giordano D, et al. Myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care. 2013;36(4):854–857. doi:10.2337/dc12-1371
   PubMed Web of Science ®Google Scholar
• Giordano D, Corrado F, Santamaria A, et al. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause. 2011;18(1):102–104. doi:10.1097/gme.0b013e3181e8e1b1
   PubMed Web of Science ®Google Scholar
• Santamaria A, Giordano D, Corrado F, et al. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric. 2012;15(5):490–495. doi:10.3109/13697137.2011.631063
   PubMed Web of Science ®Google Scholar
• Proposed International Guidelines for Biomedical Research Involving Human Subjects. The Council for International Organisation of Medical Sciences. Geneva; 1982.
   Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, et al. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med. 2010;49(16):1717–1725. doi:10.2169/internalmedicine.49.3401
   PubMed Web of Science ®Google Scholar
• American Diabetes Association 2019. Standards of medical care in diabetes. Diabetes Care. 2019;42(Suppl 1):S184–S186. doi:10.2337/dc19-Sdis01
   PubMedGoogle Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214–E223. doi:10.1152/ajpendo.1979.237.3.E214
   PubMed Web of Science ®Google Scholar
• Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York: McGraw-Hill; 1971.
   Google Scholar
• Derosa G, Bonaventura A, Bianchi L, et al. Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther. 2013;13(11):1495–1506. doi:10.1517/14712598.2013.832751
   PubMed Web of Science ®Google Scholar
• Di Pierro F, Villanova N, Agostini F, Marzocchi R, Soverini V, Marchesini G. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes. 2012;5:213–217. doi:10.2147/DMSO.S33718
   PubMedGoogle Scholar
• Derosa G, Maffioli P, Cicero AFG. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2012;12(8):1113–1124. doi:10.1517/14712598.2012.704014
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Bonaventura A, Bianchi L, Romano D, Maffioli P. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin Biol Ther. 2013;13(4):475–482. doi:10.1517/14712598.2013.776037
   PubMed Web of Science ®Google Scholar
• Momtazi AA, Derosa G, Maffioli P, Banach M, Sahebkar A. Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol Diagn Ther. 2016;20:335–345. doi:10.1007/s40291-016-0202-7
   PubMed Web of Science ®Google Scholar
• Judy WV, Hari SP, Stogsdill WW, Judy JS, Naguib YM, Passwater R. Antidiabetic activity of a standardized extract (Glucosol from Lagerstroemia speciosa leaves in type II diabetics: A dose-dependence study. J Ethnopharmacol. 2003;87:115–117. doi:10.1016/S0378-8741(03)00122-3
   PubMed Web of Science ®Google Scholar
• Minambres I, Cuixart G, Gonçalves A, Corcoy R. Effects of inositol on glucose homeostasis: systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2019;38:1146–1152. doi:10.1016/j.clnu.2018.06.957
   PubMed Web of Science ®Google Scholar